Navigation Links
Particle in Medical Technology

Particle Sciences Expands Its Combination Product Capabilities

... BETHLEHEM, Pa., Aug. 19 /PRNewswire/ -- particle Sciences Inc. has expanded its Combination ... loaded polymeric devices. This addition gives particle Sciences the ability to go from bench scale to clinical trial material production. particle Sciences has recently completed Phase I of the ...

Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds

... over other procedures for lipoprotein particle analysis because it both measures particle size accurately on the basis of ... particles present at each size independently of particle composition. We believe this approach ...

IBA and Elekta Initiate Global Particle Therapy Program at ASTRO

... EKTA.ST), today announced a global particle therapy collaboration program to optimize the ... comprehensive cancer treatment solutions to the particle therapy market. Both companies have unique ... integration of both linear accelerator and particle therapy environments will have significant added ...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

... Inc. (Nasdaq: NVAX ) announced today it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under ... diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, ...

Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

... in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase IIa randomized, ... of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, ...

Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate

... results for a new broadly immunogenic pandemic influenza virus-like particle (VLP) vaccine candidate that provided protection against several H5N1 ... of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP-based, potent, ...

Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference

... the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, ... of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP-based, potent, ...

Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin

... results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer ... and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was ...

Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development

... development of SARS vaccine candidates using Novavax's virus-like particle (VLP) technology. "Until now, it has been difficult to produce VLP ... of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, ...

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

... Wheeler C, Ferris DG, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 ... et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from ...

MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics

... proprietary Tempo inhaler. MAP0005 uses the Company's proprietary particle technology to combine the corticosteroid and beta-agonist components into a single drug particle in a fixed, pre-specified ratio. MAP Pharmaceuticals believes this ...

GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years

... al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from ... HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types ...

Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program

... studies of its recombinant trivalent seasonal influenza virus-like particle (VLP) vaccine. The trivalent seasonal influenza vaccine is the second of ... current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing ...

GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution

... bioprocess solutions and design expertise and Novavax's virus- like particle (VLP) and manufacturing platform. Health planners around the world are ... current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing ...

Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs

... development costs related to advancing the Company's two lead virus-like particle ("VLP")-based vaccine candidates against pandemic and seasonal influenza. ... current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing ...

Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference

... results of pre-clinical immunological studies of improved HIV-1 virus-like particle (VLP) vaccines being developed by scientists at Novavax and leading ... current preventives options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing ...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

... or IsoCrom. PARI's Comparative in-vitro assessment of IsoCrom & a novel 6% DSCG formulation Sophisticated aerodynamic droplet and particle size assessments in a cascade impactor operated at different humidity levels revealed how delivery and deposition performance of aerosols can be ...

Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year

... of the world's highest field, high energy cyclotron magnet. Still River's magnet is the key technical element for reducing the size and cost of the particle accelerator that will deliver proton therapy at a number of hospitals beginning with the first installation at Barnes Jewish Hospital in St. Louis, ...

MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints

... for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, ...

AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints

... for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, ...

New Proton Therapy Equipment Enables More Tumors to be Treated

... past four years by IBA in collaboration with Massachusetts General Hospital and the UF Proton Therapy Institute. IBA is the leading manufacturer of particle therapy equipment, with international headquarters in Belgium and a United States proton therapy headquarters in Jacksonville. "The immediate ...

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

... liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 ...

Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate

... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...

Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate

... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...

NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting

... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...

NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference

... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional ...

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program

... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...

Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008

... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...

Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's

... half of the radioactivity is lost every 20 minutes. This means that it must be manufactured onsite, a process that requires a cyclotron (a type of particle accelerator), which is rarely found in community hospitals. This limitation has prompted a search for longer-lived tracers, such as 18F-labeled ...

Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial

... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent recombinant vaccines utilizing a new, efficient manufacturing solution. Additional ...

FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S.

... ETDRS chart at 12 months. In contrast to previous forms of radiation therapy for wet AMD, NeoVista's therapy delivers a one-time peak dose of beta particle energy (24 Gy) directly to the lesion, and the normal retinal vasculature receives minimal exposure. Utilizing strontium 90, the focused energy is ...

Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate

... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based highly potent, recombinant vaccines utilizing a new, efficient manufacturing solution. ...

Novavax Reports Fourth Quarter and 2007 Year-End Financial Results

... creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the Company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other ...

PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial

... to PARI when developing new medications," said Lisa Cambridge, director of Clinical Development at PARI Respiratory Equipment. "Our LC STAR is a fine particle nebulizer that enables delivery of aerosols to the smaller airways of the lungs -- beneficial for successful respiratory therapies." Known as ...

Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program

... creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral ...

Novavax CEO to Present at ACUMENBioFin's 9th Annual Healthcare Conference

... creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral ...

Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission

... scale, The Eclipse family of PET cyclotrons is Siemens solution for radioisotope production. The Eclipse cyclotron is an 11 MeV, negative ion, single particle accelerator designed for clinical and commercial production and distribution of 18-fluoride-based radiotracers, as well as production N- 13, 0-15 and ...

Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol

... 5 in the journal Nature Structural & Molecular Biology in a paper entitled "The Refined Structure of Nascent HDL Reveals a Key Functional Domain for particle Maturation and Dysfunction." It builds upon the researchers' previous work which determined that not all HDL helps protect arteries from becoming ...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

... which does not bind CD20, and the standard beta particle emitting radioimmunoconjugate for CD20-positive ... that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and ... novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal ...
Other Contents
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Unidesk ... Osteopathic Medicine (ACOM), which welcomed its inaugural class ... Infrastructure (VDI) to seamlessly support bring your own ... and teaching – experience. The solution, comprised of ... , Dell server and storage infrastructure ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 No ... not been able to eradicate the head louse parasite—a ... hassle for parents. Each year between six and twelve ... Troopers, the Miami-based lice removal treatment company comes to ... non-toxic and environmentally friendly. With its track record of ...
(Date:12/17/2014)... parents should leave prenatal picture-taking to medical professionals, the ... ultrasound imaging and heartbeat monitors to get "keepsake" images ... "Although there is a lack of evidence ... monitors, prudent use of these devices by trained health ... engineer, said in an agency news release. "Ultrasound ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 ... and work commitment is a big reason why, new research ... Dr. Mathias Basner, an assistant professor of sleep and chronobiology ... Medicine. A time-use survey of nearly 125,000 Americans, ages ... activity exchanged for sleep. Short sleepers -- those who slept ...
(Date:12/15/2014)... West Palm Beach, FL (PRWEB) December 15, 2014 ... Urgent Care , knows that holidays can be a daze ... accidents. From slips and falls while decking halls, to burns ... are plenty of holiday hazards that can happen at any ... reason for pain, MD Now has made a list of ...
Breaking Medicine News(10 mins):Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3
Other TagsOther Tags